Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Cost of the Markman delay

Aside from the impact on shareprice (positive or negative) due to the unknown status, it should be costing nothing.

The extra funding you cite was tied to the Markman HEARING, not the ruling, so that should have ended last month, unless our BOD has approved something since the last communication to shareholders.

Additionally, PTSC has indicated in their last 10q, that PTSC has no intention of funding anymore of TPL's cash requirements.

Hopefully, they meant it......THIS time! lol

Share
New Message
Please login to post a reply